Skip to main content

Table 6 Frequency distribution by group of dogs with abnormalities recorded following the first treatment

From: Safety of fluralaner chewable tablets (BravectoTM), a novel systemic antiparasitic drug, in dogs after oral administration

Time point

No. of animals with abnormalities recorded per group

Analysis

Conclusion

Control group

1X group

3X group

5X group

Clinical assessment

2

5

1

1

Number of animals with abnormalities higher in 1X group than in controls, but similar to controls in 3X and 5X group; no dose–response relationship

Not treatment related

Physical examination

4

4

4

3

Number of animals with abnormalities similar to controls; no dose–response relationship

Not treatment related